Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer

Expert Reviews in Molecular Medicine

Volumn 12, Issue , 2010, Pages

  Stratford, Anna L ^a   Reipas, Kristen ^a   Maxwell, Christopher ^a   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; EPITOPE; HERMES ANTIGEN; OLAPARIB; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

CANCER GROWTH; CANCER STEM CELL; CELL FUNCTION; CELL ISOLATION; CELL SUBPOPULATION; CELL SURVIVAL; DISTANT METASTASIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR INITIATING CELL; TUMOR PROMOTION; UNSPECIFIED SIDE EFFECT; BIOLOGICAL MODEL; BREAST TUMOR; FEMALE; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77957010441     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399410001535     Document Type: Review

References (131)

1. Liedtke, C. et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 26, 1275-1281
2. Sorlie, T. et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98, 10869-10874 (Pubitemid 32878711)
3. Dent, R. et al. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 13, 4429-4434 (Pubitemid 47219710)
4. Phillips, T.M., McBride, W.H. and Pajonk, F. (2006) The response of CD24 - /low/CD44+ breast cancer-intiating cells to radiation. Journal of the National Cancer Institute 98, 1777-1785 (Pubitemid 46017929)
5. Li, X. et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute 100, 672-679
6. Wicha, M.S., Liu, S. and Dontu, G. (2006) Cancer stem cells: an old idea - a paradigm shift. Cancer Research 66, 1883-1890
7. Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 100, 3983-3988 (Pubitemid 36418143)
8. Ponti, D. et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Research 65, 5506-5511 (Pubitemid 40911148)
9. Shackleton, M. et al. (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829
10. Chuthapisith, S. et al. (2010) Breast cancer chemoresistance: emerging importance of cancer stem cells. Surgical Oncology 19, 27-32
11. Creighton, C.J. et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America 106, 13820-13825
12. Dylla, S.J. et al. (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS one 3, e2428
13. Fillmore, C.M. and Kuperwasser, C. (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Research 10, R25
14. Marangoni, E. et al. (2009) CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancer xenographs. British Journal of Cancer 100, 918-922
15. To, K. et al. (2010) YB-1 induces expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Research 70, 2840-2851
16. Jin, L. et al. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Medicine 12, 1167-1174 (Pubitemid 44527352)
17. Godar, S. et al. (2008) Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 134, 62-73 (Pubitemid 351905743)
18. Eriksson, M. et al. (2007) Oncolytic adenoviruses kill breast cancer initiating CD44 + CD24 - /low cells. Molecular Therapeutics 15, 2088-2093 (Pubitemid 350148923)
19. Stockmans, G. et al. (2008) Triple-negative breast cancer. Current Opinion in Oncology 20, 614-620
20. Tan, A.R. and Swain, S.M. (2008) Therapeutic strategies for triple-negative breast cancer. Practice of Oncology: Recent Advances 14, 343-351
21. Charafe-Jauffret, E., Ginestier, C. and Birnbaum, D. (2009) Breast cancer stem cells: tools and models to rely on. BMC Cancer 9, 202-211
22. Nakshatri, H., Srour, E.F. and Badve, S. (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Current Stem Cell Research and Therapies 4, 50-60
23. Shipitsin, M. et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273 (Pubitemid 46349843)
24. Ginestier, C. et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (Pubitemid 350056407)
25. Korkaya, H. et al. (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.Oncogene 27, 6120-6130
26. Nalwoga, H. et al. (2010) Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. British Journal of Cancer 102, 369-375
27. Dontu, G. and Wicha, M.S. (2005) Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. Journal of Mammary Gland Biology and Neoplasia 10, 75-86 (Pubitemid 40724024)
28. Finkbeiner, M.R. et al. (2009) Profiling YB-1 target genes uncovers a new mechanism for METreceptor regulation in normal and malignant human mammary cells. Oncogene 28, 1421-1431
29. Lim, E. et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine 15, 907-913
30. Asselin-Labat, M.L. et al. (2006) Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute 98, 1011-1014
31. Eirew, P. et al. (2008) A method for quantifying normal human mammary epithelial cells with in vivo regenerative ability. Nature Medicine 14, 1384-1389
32. Stingl, J. et al. (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997 (Pubitemid 43292419)
33. Visvader, J.E. (2009) Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes and Development 23, 2563-2577
34. Wallgren, A., Silfverswärd, C. and Eklund, G. (1976) Prognostic factors in mammary carcinoma. Acta Radiologica: Therapy, Physics, Biology 15, 1-16
35. Croker, A.K. et al. (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. Journal of Cellular and Molecular Medicine 13, 2236-2252
36. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Research 8, R59
37. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clinical Cancer Research 11, 1154-1159
38. Liu, R. et al. (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. New England Journal of Medicine 356, 217-226 (Pubitemid 46143225)
39. Gupta, P.B. et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 1-15
40. Pandit, T.S. et al. (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. International Journal of Oncology 35, 297-308
41. Stratford, A.L. et al. (2007) Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy. Breast Cancer Research 9, R61
42. Cheang, M.C.U. et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research 14, 1368-1376 (Pubitemid 351413917)
43. Marangoni, E. et al. (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clinical Cancer Research 13, 3989-3998 (Pubitemid 47037607)
44. Farnie, G. et al. (2007) Novel cell culture technique for primary ductal carcinoma in situ: role of notch and epidermal growth factor receptor signaling pathways. Journal of the National Cancer Institute 99, 616-627 (Pubitemid 47073543)
45. Di Leo, A. et al. (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of Clinical Oncology 26, 5544-5552
46. Finn, R.S. et al. (2009) Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. Journal of Clinical Oncology 27, 3908-3915
47. Green, M.D. et al. (2009) Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology 20, 1813-1817
48. Polychronis, A. et al. (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncology 6, 383-391 (Pubitemid 40753744)
49. Normanno, N. et al. (2008) Breast cancer cells with acquired resistance to EGFR tyrosine kinase inhibitor gefitinib show persistant activation of MAPK signaling. Breast Cancer Research and Treatment 112, 25-33
50. She, Q.-B. et al. (2003) Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clinical Cancer Research 9, 4340-4346 (Pubitemid 37248389)
51. Corkery, B. et al. (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals of Oncology 20, 862-867
52. Hoadley, K.A. et al. (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8, 258
53. Oliveras-Ferraros, C. et al. (2008) Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. International Journal of Oncology 33, 1165-1176
54. Nielsen, T. et al. (2004) Expression of the insulin-like growth factor-1 receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17 allylamino 17-demethoxy geldanamycin. Cancer Research 64, 286-291 (Pubitemid 38114109)
55. Law, J.H. et al. (2008) Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68, 10238-10246
56. Klinakis, A. et al. (2009) Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America 106, 2359-2364
57. Carboni, J.M. et al. (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Research 65, 3781-3787 (Pubitemid 40616356)
58. Kim, H.-G. et al. (2007) Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-κB and snail. Molecular and Cellular Biology 27, 3165-3175
59. Moody, S.E. et al. (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197-209 (Pubitemid 41317591)
60. Jones, R.A. et al. (2009) Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene 28, 2152-2162
61. Camp, R.L., Rimm, E.B. and Rimm, D.L. (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-2265 (Pubitemid 30010366)
62. Ghoussoub, R.A. et al. (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82, 1513-1520 (Pubitemid 28164998)
63. Welm, A.L. et al. (2005) METandMYCcooperate in mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 102, 4324-4329
64. Orian-Rousseau, V. et al. (2002) CD44 is required for two consecutive steps in HGF/c-MET signaling. Genes and Development 16, 3074-3086 (Pubitemid 35424194)
65. Graveel, C.R. et al. (2009) Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America 106, 12909-12914
66. Ponzo, M.G. et al. (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America 106, 12903-12908
67. Comoglio, P., Giordano, S. and Trusolino, L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery 7, 504-516 (Pubitemid 351767118)
68. Hines, S.J. et al. (1995) Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth & Differentiation 6, 769-779
69. Tsuda, H. et al. (2005) Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Cancer Science 96, 333-339 (Pubitemid 41007467)
70. Levina, V. et al. (2010) Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Research 70, 338-346
71. Nielsen, T.O. et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast cancer. Clinical Cancer Research 10, 5367-5374 (Pubitemid 39100473)
72. Renouf, D.J., Wilson, L. and Blanke, C.D. (2009) Successes and challenges in translational research: the development of targeted for gastrointestinal stromal tumours. Clinical Cancer Research 15, 3908-3911
73. Heinrich, M.C. et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology 21, 4342-4349 (Pubitemid 46621810)
74. Zhou, J. et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proceedings of the National Academyof Sciences of the United States of America 104, 16158-16163 (Pubitemid 350099378)
75. Eralp, Y. et al. (2008) MAPK overexpression is associatedwith anthracycline resistance andincreased risk for recurrence in patients with triple-negative breast cancer. Annals of Oncology 19, 669-674 (Pubitemid 351461036)
76. Chen, R.-H., Abate, C. and Blenis, J. (1993) Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proceedings of the National Academy of Sciences of the United States of America 90, 10952-10956 (Pubitemid 23354346)
77. Schouten, G.J. et al. (1997) IKappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO Journal 16, 3133-3144 (Pubitemid 27234953)
78. Joel, P.B. et al. (1998) pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 18, 1978-1984 (Pubitemid 28152646)
79. Stratford, A.L. et al. (2008) Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Research 10, R99
80. Shimamura, A. et al. (2000) Rsk1 mediates a MEK-MAP kinase cell survival signal. Current Biology 10, 127-135 (Pubitemid 30115743)
81. Anjum, R. et al. (2005) The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Current Biology 15, 1762-1767 (Pubitemid 41415634)
82. Larrea, M.D. et al. (2009) RSK1 drives p17Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proceedings of the National Academy of Sciences of the United States of America 106, 9268-9273
83. Clark, D.E. et al. (2005) The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Research 65, 3108-3116 (Pubitemid 40524591)
84. Cuadrado, A. and Nebreda, A.R. (2007) New insights into RSK activation and hematopoietic cancer. Cancer Cell 12, 187-189 (Pubitemid 47333422)
85. Smith, J.A. et al. (2005) Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Research 65, 1027-1034 (Pubitemid 40216465)
86. Xian, W. et al. (2009) Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Research 69, 2244-2251
87. Cho, Y.-Y. et al. (2007) Ribosomal S6 kinase 2 is a key regulator in tumor promoter-induced cell transformation. Cancer Research 67, 8104-8112 (Pubitemid 47395145)
88. Sapkota, G.P. et al. (2007) BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Journal of Biochemistry 401, 29-38 (Pubitemid 46114597)
89. Cohen, M.S., Hadjivassiliou, H. and Taunton, J. (2007) A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nature Chemical Biology 3, 156-160
90. Kleer, C.G. et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of theNational Academyof Sciences of the United States of America 100, 11606-11611
91. Suvà, M.-L. et al. (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Research 69, 9211-9218
92. Gonzalez, M.E. et al. (2009) Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28, 843-853
93. Bergmann, S. et al. (2005) YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Research 65, 4078-4087 (Pubitemid 40775644)
94. Bargou, R.C. et al. (1997) Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nature Medicine 3, 447-450 (Pubitemid 27145688)
95. Kuwano, M. et al. (2003) The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Science 94, 9-14 (Pubitemid 36575851)
96. Sutherland, B.W. et al. (2005) Akt phosphorylates the Y-box binding 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24, 4281-4292 (Pubitemid 40961781)
97. Sakura, H. et al. (1988) Two human genes isolated by a novel method encode DNA-binding proteins containing a common region of homology. Gene 73, 499-507 (Pubitemid 19043281)
98. Wu, J. et al. (2006) Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Research 66, 4872-4879
99. Astanehe, A. et al. (2009) The transcriptional induction of PIK3CAin tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 28, 2406-2418
100. Habibi, G. et al. (2008) Re-defining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research 10, R86
101. Lee, C. et al. (2008) Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Research 68, 8661-8666
102. Judge, A.D. et al. (2009) Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. Journal of Clinical Investigation 119, 661-673
103. Semple, S.C. et al. (2010) Rational design of cationic lipids for siRNA delivery.Nature Biotechnology 28, 172-176
104. Narod, S.A. and Foulkes, W.D. (2004) BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer 4, 665-676 (Pubitemid 39215065)
105. Stefansson, O.A. et al. (2009) Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Research 11, R47
106. Foulkes, W.D. (2004) BRCA1 functions as a breast stem cell regulator. Journal of Medical Genetics 41, 1-5
107. Bane, A.L. et al. (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology 31, 121-128 (Pubitemid 46036911)
108. Waddell, N. et al. (2009) Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment Dec 4; [Epub ahead of print]
109. Turner, N.C. and Reis-Filho, J.S. (2006) Basal-like breast cancer and BRCA1 phenotype. Oncogene 25, 5846-5853 (Pubitemid 44453440)
110. McCarthy, A. et al. (2007) A mouse model of basal-like breast carcinoma with metaplastic elements. Journal of Pathology 211, 389-398 (Pubitemid 46332550)
111. Deng, C.X. andWang, R.H. (2003) Roles of BRCA1 in DNA damage repair: a link between development and cancer. Human Molecular Genetics 12 Spec No 1, R113-R123
112. Bryant, H.E. et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (Pubitemid 40559005)
113. Farmer, H. et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (Pubitemid 40559006)
114. Evers, B. et al. (2008) Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clinical Cancer Research 14, 3916-3925
115. Rottenberg, S. et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America 105, 17079-17084
116. Byrski, T. et al. (2009) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. Journal of Clinical Oncology 28, 375-379
117. Carey, L.A. (2010) Targeted chemotherapy? Platinum in BRCA1-dysfuntional breast cancer. Journal of Clinical Oncology 28, 361-363
118. Evers, B. et al. (2010) A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clinical Cancer Research 16, 99-108
119. Fong, P.C. et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCAmutation carriers. New England Journal of Medicine 361, 123-134
120. Furuta, S. et al. (2005) Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 102, 9176-9181 (Pubitemid 40923537)
121. Liu, S. et al. (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of the National Academy of Sciences of the United States of America 105, 1680-1685 (Pubitemid 351346574)
122. Ginestier, C., Liu, S. andWicha, M.S. (2009) Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell 5, 229-230
123. Gautschi, O. et al. (2008) Aurora kinases as anticancer drug targets. Clinical Cancer Research 14, 1639-1648 (Pubitemid 351471713)
124. Chang, S. et al. (2009) Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. Journal of Clinical Investigation 119, 3160-3171
125. Ouchi, M. et al. (2004) BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. Journal of Biological Chemistry 279, 19643-19648 (Pubitemid 38623401)
126. Sankaran, S. et al. (2007) Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Research 67, 11186-11194 (Pubitemid 350248543)
127. Hennessy, B.T. et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research 69, 4116-4124
128. Honeth, G. et al. (2008) The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Research 10, R53
129. Tanei, T. et al. (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancer. Clinical Cancer Research 15, 4234-4241
130. Kai, K. et al. (2010) Breast cancer stem cells. Breast Cancer 17, 80-85
131. Sleeman, J.P. and Cremers, N. (2007) New concepts in breast cancer metastasis: tumour initiating cells and the microenvironment. Clinical and Experimental Metastasis 24, 707-715 (Pubitemid 50000183)